{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:15:31Z","timestamp":1780676131501,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s40261-021-01075-w","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T20:02:47Z","timestamp":1629921767000},"page":"843-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bempedoic Acid: A New Non-statin Drug for the Treatment of Dyslipidemia"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-7055","authenticated-orcid":false,"given":"Surasak","family":"Wichaiyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasu","family":"Supharattanasitthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"issue":"1","key":"1075_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"25","key":"1075_CR2","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"1","key":"1075_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20\u20138.","journal-title":"N Engl J Med"},{"issue":"20","key":"1075_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa021993","volume":"347","author":"PM Ridker","year":"2002","unstructured":"Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557\u201365.","journal-title":"N Engl J Med"},{"issue":"3","key":"1075_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jacl.2020.03.006","volume":"14","author":"RJ Romanelli","year":"2020","unstructured":"Romanelli RJ, Ito MK, Karalis DG, Huang HC, Iorga SR, Kam IW, et al. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: trends from a community-based health care delivery system, 2002\u20132016. J Clin Lipidol. 2020;14(3):305\u201314.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"1075_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1177\/0897190019825915","volume":"33","author":"Y Kunlamas","year":"2020","unstructured":"Kunlamas Y, Areepium N, Ariyachaipanich A, Bunditanukul K. Real-world effectiveness of high-versus moderate-intensity statin therapy in Thai patients with acute coronary syndrome and who had undergone primary percutaneous coronary intervention. J Pharm Pract. 2020;33(5):640\u20136.","journal-title":"J Pharm Pract"},{"key":"1075_CR7","first-page":"415","volume":"8","author":"BA Phan","year":"2012","unstructured":"Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415\u201327.","journal-title":"Vasc Health Risk Manag."},{"issue":"69","key":"1075_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev-med-042716-091351","volume":"29","author":"CN Hess","year":"2018","unstructured":"Hess CN, Low Wang CC, Hiatt WR. PCSK9 inhibitors: mechanisms of action, metabolic effects, and clinical outcomes. Annu Rev Med. 2018;29(69):133\u201345.","journal-title":"Annu Rev Med"},{"issue":"7","key":"1075_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-020-01308-w","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Bempedoic acid: first approval. Drugs. 2020;80(7):747\u201353.","journal-title":"Drugs"},{"issue":"4","key":"1075_CR10","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/hep.22774","volume":"49","author":"Q Wang","year":"2009","unstructured":"Wang Q, Jiang L, Wang J, Li S, Yu Y, You J, et al. Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice. Hepatology. 2009;49(4):1166\u201375.","journal-title":"Hepatology"},{"issue":"11","key":"1075_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","volume":"380","author":"BA Ference","year":"2019","unstructured":"Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2019;380(11):1033\u201342.","journal-title":"N Engl J Med"},{"issue":"7","key":"1075_CR12","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1056\/NEJMc1908496","volume":"383","author":"BA Ference","year":"2020","unstructured":"Ference BA, Ray KK, Nicholls SJ. Mendelian randomization study of ACLY and cardiovascular disease. Reply. N Engl J Med. 2020;383(7):e50.","journal-title":"N Engl J Med"},{"issue":"7","key":"1075_CR13","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1056\/NEJMc1908496","volume":"383","author":"A Damask","year":"2020","unstructured":"Damask A, Paulding C, Baras A, Carey D, Abecasis GR. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2020;383(7):e50.","journal-title":"N Engl J Med"},{"issue":"7","key":"1075_CR14","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1056\/NEJMc1908496","volume":"383","author":"H Holm","year":"2020","unstructured":"Holm H, Sulem P, Helgadottir A, Tragante V, Thornorleifsson G, Guethbjartsson D, et al. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2020;383(7):e50.","journal-title":"N Engl J Med"},{"issue":"7","key":"1075_CR15","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1056\/NEJMc1908496","volume":"383","author":"D Klarin","year":"2020","unstructured":"Klarin D, O\u2019Donnell CJ, Kathiresan S. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2020;383(7):e50.","journal-title":"N Engl J Med"},{"issue":"7","key":"1075_CR16","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1194\/jlr.M400018-JLR200","volume":"45","author":"CT Cramer","year":"2004","unstructured":"Cramer CT, Goetz B, Hopson KL, Fici GJ, Ackermann RM, Brown SC, et al. Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J Lipid Res. 2004;45(7):1289\u2013301.","journal-title":"J Lipid Res"},{"issue":"1","key":"1075_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1194\/jlr.M030528","volume":"54","author":"SL Pinkosky","year":"2013","unstructured":"Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134\u201351.","journal-title":"J Lipid Res"},{"issue":"7","key":"1075_CR18","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"28","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;28(7):13457.","journal-title":"Nat Commun"},{"issue":"9","key":"1075_CR19","first-page":"817","volume":"11","author":"A Mendoza-Oliva","year":"2014","unstructured":"Mendoza-Oliva A, Zepeda A, Arias C. The complex actions of statins in brain and their relevance for Alzheimer\u2019s disease treatment: an analytical review. Curr Alzheimer Res. 2014;11(9):817\u201333.","journal-title":"Curr Alzheimer Res"},{"key":"1075_CR20","doi-asserted-by":"publisher","first-page":"101006","DOI":"10.1016\/j.plipres.2019.101006","volume":"77","author":"X Feng","year":"2020","unstructured":"Feng X, Zhang L, Xu S, Shen AZ. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: an updated review. Prog Lipid Res. 2020;77:101006.","journal-title":"Prog Lipid Res"},{"issue":"4","key":"1075_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1161\/ATVBAHA.116.308963","volume":"37","author":"JP Samsoondar","year":"2017","unstructured":"Samsoondar JP, Burke AC, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, et al. Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr(-\/-) mice by treatment with the ATP-Citrate lyase inhibitor bempedoic acid. Arterioscler Thromb Vasc Biol. 2017;37(4):647\u201356.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1075_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10557-021-07147-5","volume":"5","author":"CM Ballantyne","year":"2021","unstructured":"Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of bempedoic acid in clinical practice. Cardiovasc Drugs Ther. 2021;5:853\u201364.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"1075_CR23","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.celrep.2016.09.069","volume":"17","author":"S Zhao","year":"2016","unstructured":"Zhao S, Torres A, Henry RA, Trefely S, Wallace M, Lee JV, et al. ATP-citrate lyase controls a glucose-to-acetate metabolic switch. Cell Rep. 2016;17(4):1037\u201352.","journal-title":"Cell Rep"},{"issue":"5","key":"1075_CR24","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1161\/ATVBAHA.117.310676","volume":"38","author":"AC Burke","year":"2018","unstructured":"Burke AC, Telford DE, Sutherland BG, Edwards JY, Sawyez CG, Barrett PHR, et al. Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR(+\/-) and LDLR(-\/-)) Yucatan miniature pigs. Arterioscler Thromb Vasc Biol. 2018;38(5):1178\u201390.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1075_CR25","doi-asserted-by":"publisher","first-page":"632526","DOI":"10.3389\/fimmu.2021.632526","volume":"12","author":"M Dominguez","year":"2021","unstructured":"Dominguez M, Brune B, Namgaladze D. Exploring the role of ATP-citrate lyase in the immune system. Front Immunol. 2021;12:632526.","journal-title":"Front Immunol"},{"issue":"1","key":"1075_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbrc.2013.09.037","volume":"440","author":"V Infantino","year":"2013","unstructured":"Infantino V, Iacobazzi V, Palmieri F, Menga A. ATP-citrate lyase is essential for macrophage inflammatory response. Biochem Biophys Res Commun. 2013;440(1):105\u201311.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1075_CR27","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1038\/s41467-020-20141-z","volume":"11","author":"J Baardman","year":"2020","unstructured":"Baardman J, Verberk SGS, van der Velden S, Gijbels MJJ, van Roomen C, Sluimer JC, et al. Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques. Nat Commun. 2020;11(1):6296.","journal-title":"Nat Commun"},{"issue":"8","key":"1075_CR28","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1194\/jlr.M035212","volume":"54","author":"S Filippov","year":"2013","unstructured":"Filippov S, Pinkosky SL, Lister RJ, Pawloski C, Hanselman JC, Cramer CT, et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013;54(8):2095\u2013108.","journal-title":"J Lipid Res"},{"issue":"11","key":"1075_CR29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"18","key":"1075_CR30","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780\u20138.","journal-title":"JAMA"},{"issue":"7","key":"1075_CR31","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.","journal-title":"J Am Heart Assoc"},{"key":"1075_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","volume":"277","author":"CM Ballantyne","year":"2018","unstructured":"Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195\u2013203.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1075_CR33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12933-020-01101-9","volume":"19","author":"X Wang","year":"2020","unstructured":"Wang X, Zhang Y, Tan H, Wang P, Zha X, Chong W, et al. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020;19(1):128.","journal-title":"Cardiovasc Diabetol"},{"issue":"235","key":"1075_CR34","first-page":"104","volume":"24","author":"S Nicholls","year":"2020","unstructured":"Nicholls S, Lincoff AM, Bays HE, Cho L, Grobbee DE, Kastelein JJ, et al. Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2020;24(235):104\u201312.","journal-title":"Am Heart J"},{"issue":"10","key":"1075_CR35","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.4158\/CS-2020-0490","volume":"26","author":"Y Handelsman","year":"2020","unstructured":"Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm\u20142020 executive summary. Endocr Pract. 2020;26(10):1196\u2013224.","journal-title":"Endocr Pract"},{"issue":"5","key":"1075_CR36","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","volume":"14","author":"HE Bays","year":"2020","unstructured":"Bays HE, Banach M, Catapano AL, Duell PB, Gotto AM Jr, Laufs U, et al. Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020;14(5):649-59 e6.","journal-title":"J Clin Lipidol"},{"key":"1075_CR37","doi-asserted-by":"publisher","unstructured":"Backes JM, Hilleman DE. New and emerging lipid-lowering therapy. Future Cardiol. 2021. https:\/\/doi.org\/10.2217\/fca-2020-0217.","DOI":"10.2217\/fca-2020-0217"},{"issue":"9","key":"1075_CR38","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1124\/dmd.114.058412","volume":"42","author":"A Kunze","year":"2014","unstructured":"Kunze A, Huwyler J, Camenisch G, Poller B. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos. 2014;42(9):1514\u201321.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1075_CR39","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jacl.2019.05.003","volume":"13","author":"ND Lalwani","year":"2019","unstructured":"Lalwani ND, Hanselman JC, MacDougall DE, Sterling LR, Cramer CT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial. J Clin Lipidol. 2019;13(4):568\u201379.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"1075_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/ajhp\/zxaa352","volume":"78","author":"D Delevry","year":"2021","unstructured":"Delevry D, Gupta EK. Bempedoic acid: review of a novel therapy in lipid management. Am J Health Syst Pharm. 2021;78(2):95\u2013104.","journal-title":"Am J Health Syst Pharm"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01075-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01075-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01075-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T17:06:43Z","timestamp":1632935203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01075-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01075-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"8 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding support for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that there are no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SW designed the concept and structure of the review. SW reviewed the pharmacological properties and clinical studies. WS assisted with the interpretation of the preclinical and clinical studies. SW drafted the manuscript. SW and WS critically reviewed and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}